A randomized, open-label, 2-arm, multicentre, Phase II study to evaluate the safety and efficacy of Trivax, a dendritic cell-based interleukin-12 secreting autologous cancer vaccine, in combination with Sunitinib compared with Sunitinib alone as first line treatment for patients with metastatic renal-cell carcinoma (mRCC).
- Registry ID
- EUCTR2007-002556-41
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- Trimed Biotech GmbH
- Start date
- 2008-02-07
- Completion date
- 2011-03-28
- Last update
- 2026-08-16
Conditions
- Metastatic renal cell carcinoma
Summary
To evaluate efficacy and safety of Trivax in patients with metastatic renal cell carcinoma who are treated with Sunitinib.
Locations
View on source registry